Clinical Trials in Gastroenterology and Hepatology

The Division of Gastroenterology and Hepatology is currently recruiting for the following clinical trials. For a complete list of available clinical trials, please visit the database at the Johns Hopkins Institute for Clinical and Translational Research. You can also search by condition, researcher or doctor’s name.

The Cancer of the Pancreas Screening (CAPS) 5 Study

Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Principal Investigator at each site will be responsible for internal monitoring at their site.

Protocol Number: NCT 02000089

Crohn's Disease and Ulcerative Colitis Study

his research is being done to find out why inflammatory bowel disease (IBD) (i.e., Crohn's disease and ulcerative colitis) occurs in individuals and in families. Specifically, researchers will use some of the cells from participants to help find the genes (DNA), and biomarkers that may be associated with the development of IBD, differentiate IBD types and predict IBD disease course and response to treatment.

Protocol Number: NA_00041583

Evaluation of Effect of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium

This is a feasibility study without a primary study hypothesis or statistical comparison.

Protocol Number: NCT 01633441

Familial Barrett's Esophagus (BE)

his is a multi-center study whose aim is to define the epidemiology and genetics of Barrett's esophagus and adenocarcinoma. The researchers have studied families affected with Barrett's esophagus and esophageal adenocarcinoma, a specific type of cancer of the esophagus. They have found that Barrett's and esophageal cancer occur at a younger age in these families suggesting that familial Barrett's esophagus is a genetically inherited disease.

Protocol Number: NCT 00288119

Gene Expression in IBD

The causes of inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC), are unknown and diagnosing them is often difficult. This research is being done to find the genes that may increase the risk of inflammatory bowel disease, and to identify specific protein substances that are related to IBD. The investigators are also looking at cell factors that may predict response to treatment for IBD. In IBD, cells of the gastrointestinal tract (your gut) do not seem to respond to certain substances in a normal way. Scientists have discovered that the immune system, made up of cells and chemicals that defend your body from infections, is working in a way that damages the walls of the gut. You are being asked to join in this study because you are going to have a surgical procedure performed related to your diagnosis of Crohn's disease or ulcerative colitis or for other medical reasons (for comparison purposes). If you join this study, the investigators will study the cells in the resected tissue from your gut to find out why some cells do not act in the normal way in people with IBD as compared to people without IBD. The more the investigators understand about how differently these cells are working, the better doctors and scientists will be able to someday help people with IBD.

Protocol Number: NA_00038329

Multi-Center African American IBD Study (MAAIS)

The investigators are doing the research to discover genes that cause Inflammatory Bowel Disease (IBD) specifically in the African American population. If you agree to join the study, the investigators ask that you give us information about your health. The investigators will also ask you to give us a blood sample so that they may discover the genes that cause IBD. The blood sample may be collected at Johns Hopkins or any local facility convenient to you.

Protocol Number: NA_00041578

Predicting Risk of Cancer in Barrett's Esophagus (BE)

The purpose of this study is to determine if there are any early changes in DNA markers of blood and esophageal tissue in people with gastric reflux, Barrett's esophagus or esophageal cancer that can warn of a progression to esophageal cancer.

Protocol Number: NCT 00431756

The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonscopy

Evaluation of the histologically proven adenoma and carcinoma detection rate in patients undergoing a full colonoscopy with and without mucosal contrast enhancement, obtained with 200 mg of Methylene Blue MMX® tablets.

Protocol Number: NCT 01694966

Request an Appointment

For locations in Maryland

Phone Number: 410-933-7495

Fax Numbers:
Gastroenterology: 410-500-4267
Hepatology: 410-500-4257

For locations in the National Capital Region/Washington, DC

Phone Number: 202-660-5555

Fax Numbers:
Gastroenterology: 202-660-6103
Hepatology: 202-660-7359

Already a Patient?

Request your next appointment through MyChart!

Traveling for Care?

Whether you're crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.